Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls.

Tekin S, Bir LS, Avci E, Şenol H, Tekin I, Çınkır U

Cureus18 Jul 2022Cited by 4 (Europe PMC)

PMID35989823PMCIDPMC9385168DOI10.7759/cureus.26981PepBankPUB-35989823

Summary

Background Multiple sclerosis (MS) is a major global problem, and as its pathogenesis is understood more clearly, therapeutic options expand accordingly. The mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) is a novel mitochondria-derived protein acting on metabolic homeostasis. In this study, we aimed to investigate the role of serum MOTS-c in the pathophysiology of the disease in MS patients and to discuss the mechanism of MOTS-c. Methodology In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study. MOTS-c, fasting blood glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), lipid panel, and body mass index levels were assessed. Results The participants' MOTS-c levels remained significantly lower than that of the control group, while their fasting blood glucose and HOMA-IR values were higher. The multivariate logistic regression analysis established that increased MOTS-c levels could be a protective factor against the development of MS disease. The area under the receiver operating characteristic curve for MOTS-c was calculated as 0.782 (95% confidence interval = 0.684-0.879, p = 0.0001). Conclusions This study is the first to scrutinize MOTS-c levels in MS patients. We tried to provide clinical evidence that MOTS-c could act as a highly discriminative biomarker between MS patients and control groups, which may hold great promise for future therapeutic options.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In adults with relapsing-remitting multiple sclerosis, the body's own serum MOTS‑c levels were significantly lower than in healthy controls.
In plain wordsPeople with relapsing-remitting multiple sclerosis had lower natural MOTS‑c levels in blood than healthy people.
Peptide
MOTS-c
Outcome
DecreaseSerum MOTS-c in relapsing-remitting MS versus healthy controls
Study
n = 84
Comparator
Healthy controls
Outcome group
Mitochondrial function · Nervous system and cognition
Source sentences
Summary
The participants' MOTS-c levels remained significantly lower than that of the control group, while their fasting blood glucose and HOMA-IR values were higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Methodology In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3598982301
02HumanEndogenous levelObservational studyOther
In multivariate logistic regression, higher serum MOTS‑c levels were a protective factor against multiple sclerosis.
In plain wordsHigher natural MOTS‑c levels were linked to a lower chance of having multiple sclerosis.
Peptide
MOTS-c
Outcome
Not applicableMOTS-c level as protective factor against MS
Study
n = 84
Outcome group
Mitochondrial function · Nervous system and cognition
Source sentences
Summary
The multivariate logistic regression analysis established that increased MOTS-c levels could be a protective factor against the development of MS disease.
1 context sentence(design, population, supporting numbers)
Summary · context
Methodology In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3598982302
03HumanEndogenous levelObservational studyOther
The area under the ROC curve for serum MOTS‑c in separating MS patients from controls was 0.782.
In plain wordsNatural MOTS‑c levels separated people with multiple sclerosis from healthy people with moderate accuracy.
Peptide
MOTS-c
Outcome
Not applicableDiagnostic accuracy of MOTS-c for MS
Study
n = 84
Outcome group
Mitochondrial function · Nervous system and cognition
Measurements
AUC
0.782
MS versus controls
Source sentences
Summary
The area under the receiver operating characteristic curve for MOTS-c was calculated as 0.782 (95% confidence interval = 0.684-0.879, p = 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Methodology In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3598982303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.